The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment

Karin Purshouse; John P. Thomson; Mahéva Vallet; Lorna Alexander; Isaac Bonisteel; Maree Brennan; David A. Cameron; Jonine D. Figueroa; Elizabeth Furrie; Pamela Haig; Mattea Heck; Hugh McCaughan; Paul Mitchell; Heather McVicars; Lorraine Primrose; Ines Silva; Kate Templeton; Natalie Wilson; Peter S. Hall

doi:10.1093/oncolo/oyac257

The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment

Karin Purshouse, John P. Thomson, Mahéva Vallet, Lorna Alexander, Isaac Bonisteel, Maree Brennan, David A. Cameron, Jonine D. Figueroa, Elizabeth Furrie, Pamela Haig, Mattea Heck, Hugh McCaughan, Paul Mitchell, Heather McVicars, Lorraine Primrose, Ines Silva, Kate Templeton, Natalie Wilson, Peter S. Hall (Lead / Corresponding author)

Undergraduate Medicine

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

53 Downloads (Pure)

Abstract

Background: Cancer and anti-cancer treatment (ACT) may be risk factors for severe SARS-CoV-2 infection and limited vaccine efficacy. Long-term longitudinal studies are needed to evaluate these risks. The Scottish COVID cancer immunity prevalence (SCCAMP) study characterizes the incidence and outcomes of SARS-CoV-2 infection and vaccination in patients with solid tumors undergoing ACT. This preliminary analysis includes 766 patients recruited since May 2020.

Methods: Patients with solid-organ cancers attending secondary care for active ACT consented to the collection of routine electronic health record data and serial blood samples over 12 months. Blood samples were tested for total SARS-CoV-2 antibody.

Results: A total of 766 participants were recruited between May 28, 2020 and October 31, 2021. Most received cytotoxic chemotherapy (79%). Among the participants, 48 (6.3%) were tested positive for SARS-CoV-2 by PCR. Infection rates were unaffected by ACT, largely aligning with the local population. Mortality proportion was not higher with a recent positive SARS-CoV-2 PCR (10.4% vs 10.6%). Multivariate analysis revealed lower infection rates in vaccinated patients regardless of chemotherapy (HR 0.307 [95% CI, 0.144-0.6548]) or immunotherapy (HR 0.314 [95% CI, 0.041-2.367]) treatment. A total of 96.3% of patients successfully raised SARS-CoV-2 antibodies after >2 vaccines. This was independent of the treatment type.

Conclusion: This is the largest on-going longitudinal real-world dataset of patients undergoing ACT during the early stages of the COVID-19 pandemic. This preliminary analysis demonstrates that patients with solid tumors undergoing ACT have high protection from SARS-CoV-2 infection following COVID-19 vaccination. The SCCAMP study will evaluate long-term COVID-19 antibody trends, focusing on specific ACTs and patient subgroups.

Original language	English
Pages (from-to)	e145–e155
Number of pages	11
Journal	Oncologist
Volume	28
Issue number	3
Early online date	31 Jan 2023
DOIs	https://doi.org/10.1093/oncolo/oyac257
Publication status	Published - Mar 2023

Keywords

SARS-CoV-2
COVID-19
SCCAMP
anti-cancer treatment
chemotherapy

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/oncolo/oyac257Licence: CC BY

Final Published VersionFinal published version, 721 KBLicence: CC BY

Cite this

Purshouse, K., Thomson, J. P., Vallet, M., Alexander, L., Bonisteel, I., Brennan, M., Cameron, D. A., Figueroa, J. D., Furrie, E., Haig, P., Heck, M., McCaughan, H., Mitchell, P., McVicars, H., Primrose, L., Silva, I., Templeton, K., Wilson, N., & Hall, P. S. (2023). The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment. Oncologist, 28(3), e145–e155. https://doi.org/10.1093/oncolo/oyac257

@article{b9b946a05ec241228bff8abd2f326573,

title = "The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment",

abstract = "Background: Cancer and anti-cancer treatment (ACT) may be risk factors for severe SARS-CoV-2 infection and limited vaccine efficacy. Long-term longitudinal studies are needed to evaluate these risks. The Scottish COVID cancer immunity prevalence (SCCAMP) study characterizes the incidence and outcomes of SARS-CoV-2 infection and vaccination in patients with solid tumors undergoing ACT. This preliminary analysis includes 766 patients recruited since May 2020.Methods: Patients with solid-organ cancers attending secondary care for active ACT consented to the collection of routine electronic health record data and serial blood samples over 12 months. Blood samples were tested for total SARS-CoV-2 antibody.Results: A total of 766 participants were recruited between May 28, 2020 and October 31, 2021. Most received cytotoxic chemotherapy (79%). Among the participants, 48 (6.3%) were tested positive for SARS-CoV-2 by PCR. Infection rates were unaffected by ACT, largely aligning with the local population. Mortality proportion was not higher with a recent positive SARS-CoV-2 PCR (10.4% vs 10.6%). Multivariate analysis revealed lower infection rates in vaccinated patients regardless of chemotherapy (HR 0.307 [95% CI, 0.144-0.6548]) or immunotherapy (HR 0.314 [95% CI, 0.041-2.367]) treatment. A total of 96.3% of patients successfully raised SARS-CoV-2 antibodies after >2 vaccines. This was independent of the treatment type.Conclusion: This is the largest on-going longitudinal real-world dataset of patients undergoing ACT during the early stages of the COVID-19 pandemic. This preliminary analysis demonstrates that patients with solid tumors undergoing ACT have high protection from SARS-CoV-2 infection following COVID-19 vaccination. The SCCAMP study will evaluate long-term COVID-19 antibody trends, focusing on specific ACTs and patient subgroups.",

keywords = "SARS-CoV-2, COVID-19, SCCAMP, anti-cancer treatment, chemotherapy",

author = "Karin Purshouse and Thomson, {John P.} and Mah{\'e}va Vallet and Lorna Alexander and Isaac Bonisteel and Maree Brennan and Cameron, {David A.} and Figueroa, {Jonine D.} and Elizabeth Furrie and Pamela Haig and Mattea Heck and Hugh McCaughan and Paul Mitchell and Heather McVicars and Lorraine Primrose and Ines Silva and Kate Templeton and Natalie Wilson and Hall, {Peter S.}",

note = "Funding Information: Funding was provided by the NHS Lothian Charity. Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press.",

year = "2023",

month = mar,

doi = "10.1093/oncolo/oyac257",

language = "English",

volume = "28",

pages = "e145–e155",

journal = "Oncologist",

issn = "1083-7159",

publisher = "Oxford University Press",

number = "3",

}

Purshouse, K, Thomson, JP, Vallet, M, Alexander, L, Bonisteel, I, Brennan, M, Cameron, DA, Figueroa, JD, Furrie, E, Haig, P, Heck, M, McCaughan, H, Mitchell, P, McVicars, H, Primrose, L, Silva, I, Templeton, K, Wilson, N & Hall, PS 2023, 'The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment', Oncologist, vol. 28, no. 3, pp. e145–e155. https://doi.org/10.1093/oncolo/oyac257

TY - JOUR

T1 - The Scottish COVID Cancer Immunity Prevalence Study

T2 - A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment

AU - Purshouse, Karin

AU - Thomson, John P.

AU - Vallet, Mahéva

AU - Alexander, Lorna

AU - Bonisteel, Isaac

AU - Brennan, Maree

AU - Cameron, David A.

AU - Figueroa, Jonine D.

AU - Furrie, Elizabeth

AU - Haig, Pamela

AU - Heck, Mattea

AU - McCaughan, Hugh

AU - Mitchell, Paul

AU - McVicars, Heather

AU - Primrose, Lorraine

AU - Silva, Ines

AU - Templeton, Kate

AU - Wilson, Natalie

AU - Hall, Peter S.

PY - 2023/3

Y1 - 2023/3

N2 - Background: Cancer and anti-cancer treatment (ACT) may be risk factors for severe SARS-CoV-2 infection and limited vaccine efficacy. Long-term longitudinal studies are needed to evaluate these risks. The Scottish COVID cancer immunity prevalence (SCCAMP) study characterizes the incidence and outcomes of SARS-CoV-2 infection and vaccination in patients with solid tumors undergoing ACT. This preliminary analysis includes 766 patients recruited since May 2020.Methods: Patients with solid-organ cancers attending secondary care for active ACT consented to the collection of routine electronic health record data and serial blood samples over 12 months. Blood samples were tested for total SARS-CoV-2 antibody.Results: A total of 766 participants were recruited between May 28, 2020 and October 31, 2021. Most received cytotoxic chemotherapy (79%). Among the participants, 48 (6.3%) were tested positive for SARS-CoV-2 by PCR. Infection rates were unaffected by ACT, largely aligning with the local population. Mortality proportion was not higher with a recent positive SARS-CoV-2 PCR (10.4% vs 10.6%). Multivariate analysis revealed lower infection rates in vaccinated patients regardless of chemotherapy (HR 0.307 [95% CI, 0.144-0.6548]) or immunotherapy (HR 0.314 [95% CI, 0.041-2.367]) treatment. A total of 96.3% of patients successfully raised SARS-CoV-2 antibodies after >2 vaccines. This was independent of the treatment type.Conclusion: This is the largest on-going longitudinal real-world dataset of patients undergoing ACT during the early stages of the COVID-19 pandemic. This preliminary analysis demonstrates that patients with solid tumors undergoing ACT have high protection from SARS-CoV-2 infection following COVID-19 vaccination. The SCCAMP study will evaluate long-term COVID-19 antibody trends, focusing on specific ACTs and patient subgroups.

AB - Background: Cancer and anti-cancer treatment (ACT) may be risk factors for severe SARS-CoV-2 infection and limited vaccine efficacy. Long-term longitudinal studies are needed to evaluate these risks. The Scottish COVID cancer immunity prevalence (SCCAMP) study characterizes the incidence and outcomes of SARS-CoV-2 infection and vaccination in patients with solid tumors undergoing ACT. This preliminary analysis includes 766 patients recruited since May 2020.Methods: Patients with solid-organ cancers attending secondary care for active ACT consented to the collection of routine electronic health record data and serial blood samples over 12 months. Blood samples were tested for total SARS-CoV-2 antibody.Results: A total of 766 participants were recruited between May 28, 2020 and October 31, 2021. Most received cytotoxic chemotherapy (79%). Among the participants, 48 (6.3%) were tested positive for SARS-CoV-2 by PCR. Infection rates were unaffected by ACT, largely aligning with the local population. Mortality proportion was not higher with a recent positive SARS-CoV-2 PCR (10.4% vs 10.6%). Multivariate analysis revealed lower infection rates in vaccinated patients regardless of chemotherapy (HR 0.307 [95% CI, 0.144-0.6548]) or immunotherapy (HR 0.314 [95% CI, 0.041-2.367]) treatment. A total of 96.3% of patients successfully raised SARS-CoV-2 antibodies after >2 vaccines. This was independent of the treatment type.Conclusion: This is the largest on-going longitudinal real-world dataset of patients undergoing ACT during the early stages of the COVID-19 pandemic. This preliminary analysis demonstrates that patients with solid tumors undergoing ACT have high protection from SARS-CoV-2 infection following COVID-19 vaccination. The SCCAMP study will evaluate long-term COVID-19 antibody trends, focusing on specific ACTs and patient subgroups.

KW - SARS-CoV-2

KW - COVID-19

KW - SCCAMP

KW - anti-cancer treatment

KW - chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85150666442&partnerID=8YFLogxK

U2 - 10.1093/oncolo/oyac257

DO - 10.1093/oncolo/oyac257

M3 - Article

C2 - 36719033

SN - 1083-7159

VL - 28

SP - e145–e155

JO - Oncologist

JF - Oncologist

IS - 3

ER -

The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this